Anti-SARS-CoV-2 neutralizing monoclonal antibodies: clinical pipeline.

Article Details

Citation

Copy to clipboard

Tuccori M, Ferraro S, Convertino I, Cappello E, Valdiserra G, Blandizzi C, Maggi F, Focosi D

Anti-SARS-CoV-2 neutralizing monoclonal antibodies: clinical pipeline.

MAbs. 2020 Jan-Dec;12(1):1854149. doi: 10.1080/19420862.2020.1854149.

PubMed ID

33319649 [ View in PubMed

]

Abstract

Monoclonal antibody (mAb) therapy has been previously exploited for viral infections, such as respiratory syncytial virus pneumonia and Ebolavirus disease. In the ongoing COVID-19 pandemic, early signals of efficacy from convalescent plasma therapy have encouraged research and development of anti-SARS-CoV-2 mAbs. While many candidates are in preclinical development, we focus here on anti-SARS-CoV-2 neutralizing mAbs (or mAb cocktails) that represent the late-stage clinical pipeline, i.e., those currently in Phase 2 or Phase 3 clinical trials. We describe the structure, mechanism of action, and ongoing trials for VIR-7831, LY-CoV555, LY-CoV016, BGB-DXP593, REGN-COV2, and CT-P59. We speculate also on the next generation of these mAbs.

DrugBank Data that Cites this Article

Drugs

Sotrovimab

Regdanvimab

Drug Targets

Drug	Target	Kind	Organism	Pharmacological Action	Actions
Sotrovimab	Spike glycoprotein	Protein	SARS-CoV-2	Unknown	Binder	Details